Classic galactosemia: features of diagnosis and treatment

N.O. Pichkur, N.V. Olkhovych, Ya.I. Doronina

Abstract


Background. Galactosemia type I, or classic galactosemia (CG), is the most severe form of hereditary disorders of carbohydrate metabolism, in particular, galactose. Galactosemia is not included in the program of massive neonatal screening in Ukraine. The CG is characterized by the non-specific onset symptoms and leads to high mortality among infants in the neonatal period. The problem of early diagnosis and treatment of infants with CG in the absence of a program for massive neonatal screening in Ukraine requires solution. The purpose was to analyse the clinical and laboratory, molecular genetic features of patients with CG; to define a set of clinical symptoms and to form selective groups of patients for administration of diet therapy and laboratory diagnosis; to develop schemes-stages of effective early diagnosis and treatment of patients with CG in the absence of mass neonatal screening in order to reduce infant mortality and prevent the disability of patients with this pathology. Materials and methods. In 2014–2017, 317 patients with a diagnosis of hepatitis of uncertain origin were examined. The age of patients ranged from 3 days to 16 years; 145 (45 %) of them were males, 172 (55 %) — females. In all patients, a polysyndromic clinical picture with predominant lesion in the liver function was observed. All patients were examined for the activity of galactose-1-phosphate uridylyltransferase (GALT) enzyme in the red blood cells and underwent DNA diagnosis for the detection of major mutations in the GALT gene. All patients were examined for viral hepatitis, underwent biochemical blood tests for hepatic transaminases, alkaline phosphatase, bilirubin levels, and coagulopathy. Tandem mass spectrometry was also performed to exclude or confirm the metabolic imbalance of amino acids, organic acids, and mitochondrial beta-oxi­dation of fatty acids. Five patients with suspected glycogenosis have been subjected to a quantitative glycogen test in the liver biopsy sample. Results. The diagnosis of CG was established in 15 (5 %) of 317 patients. Male/female ratio was 9 : 6, patient’s age ranged from 14 days to 15 years at the time of investigation in the Center. In 13 out of 15 children, the clinical diagnosis of CG was made on average of 47 days of life (47 ± 15 days). In two patients, the CG was diagnosed at the age of 2 and 15 years. In all patients, the activity of GALT enzyme in erythrocytes was reduced and ranged from 0.08 to 5.8 U/g Hb (mean value 3.3 ± 1.6 U/g Hb) at a normal value > 10 U/g Hb. Molecular genetic analysis was performed in 14 patients. Five patients had a homozygous genotype of Q188R, 1 patient — homozygous K285N genotype, 6 patients were heterozygotes in two major mutations, Q188R and K285N (genotype Q188R/K285N); one patient had р.Y209S/р.K285N genotype, another one — р.K285N mutation only in one allele. Thus, 28 alleles in the GALT gene were examined from 14 patients and 27 mutations were identified: Q188R —57 %, K285N — 36 %, Y209S — 3 % (detected in one patient in one allele). The mutations Q188R and K285N together amounted to 93 % indicating a high level among Ukrainian population. Cataract has been diagnosed in 6 patients (40 %). In our group of CG patients, in all of them it was combined with neurological symptoms. Defeats of the nervous system (cognitive deficiency, spastic tetraparesis, dystonia, tremor and disorders in the form of dysarthria and delayed speech development) were noted in 7 CG patients (47 %). The analysis of the mortality in this group showed that it was 27 % (4 of 15 patients dead at the age of 24 days to 2.5 months). Additionally, the analysis of families with CG patients showed frequent cases of early death from liver failure in the age up to 14 weeks. In three families, there were four deaths in the neonatal period. If we consider all dead children with similar symptoms in the families with CG patients, then the percentage of deceased patients would be 47 % (8 of 19 children born in families with CG). In all cases, treatment was started too late, on average on day 44. Jaundice was observed in 93 % of CG patients, hepatomegaly — in 80 %, dyspeptic manifestations — in 87 %. The scheme has been proposed of stages of diagnostic and therapeutic measures in the selective group with suspected CG. Conclusions. CG is a life-threatening disease characterized by severe hepatocellular lesions, dyspeptic syndrome, sepsis, and high mortality in the neonatal period. Mutations Q188R and K285N together make up 93 % that indicates a high level in Ukraine. All infants with jaundice due to hyperbilirubinemia, hepatomegaly, dyspeptic disorders, high levels of transaminases, and blood clotting disorders should be screened for the presence of CG and urgently change the diet to lactose-free one, until the results of the confirmatory laboratory diagnosis are obtained.


Keywords


galactosemia; classic galactosemia; activity of GALT enzyme; lactose-free diet

References


Sarafoglou K, Hoffmann GF, Roth KS. Pediatric Endocrinology And Inborn Errors Of Metabolism. 2nd ed. United States: McGraw-Hill Education; 2017. 127-134 pp.

Berry GT, Elsas LJ. Introductoin to the Maasticht workshop on galactosemia: lessons from the past and new directions in galactosemia. J Inherit Metab Dis. 2011 Apr;34(2):249-55. doi: 10.1007/s10545-010-9232-1.

Welling L, Bernstein LE, Berry GT, et al. International clinical guideline for the management of classical galactosemia: diagnosis, treatment, and follow-up. J Inherit Metab Dis. 2017 Mar;40(2):171-176. doi: 10.1007/s10545-016-9990-5.

Berry GT. Classic Galactosemia and Clinical Variant Galactosemia. 2000 Feb 4 [Updated 2017 Mar 9]. In: Adam MP, Ardinger HH, Pagon RA, et al, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018.

Ridel K, Leslie N, Gilbert D. An updated review of the long-term neurological effects of galactosemia. Pediatr Neurol. 2005 Sep;33(3):153-61. doi:10.1016/j.pediatrneurol.2005.02.015.

Rubio-Agusti I, Carecchio M, Bhatia KP, et al. Movement disorders in adult patients with classical galactosemia. Mov Disord. 2013 Jun;28(6):804-10. doi: 10.1002/mds.25348.

Van Calcar SC, Bernstein LE, Rohr FJ, Yannicelli S, Berry GT, Scaman CH. Galactose content of legumes, caseinates, and some hard cheeses: implications for diet treatment of classic galactosemia. J Agric Food Chem. 2014 Feb 12;62(6):1397-402. doi: 10.1021/jf404995a.

Lampret BR, Murko S, Tanšek MŽ, et al. Selective screening for metabolic disorders in the Slovenian pediatric population. J Med Biochem. 2015 Jan;34(1):58-63. doi: 10.2478/jomb-2014-0056.

Coss KP, Doran PP, Owoeye C, et al. Classical galactosemia in Ireland: incidence, complications and outcomes of treatment. J Inherit Metab Dis. 2013 Jan;36(1):21-7. doi: 10.1007/s10545-012-9507-9.

Baranov AA, Borovik TE, Bushueva ТV, Zhurkova NV, Zakharova EYu, Zvonkova NG, Kuzenkova LM, Kutsev SI. Federal'nyye klinicheskiye rekomendatsii po diagnostike i lecheniyu galaktozemii, 2016 [Federal clinical guidelines for the diagnosis and treatment of galactosemia, 2016]. Available from: http://www.pediatr-russia.ru/news/recomend.

Tyfield L, Reichardt J, Fridovich-Keil J, et al. Classical galactosemia and mutations at the galactose-1-phosphate uridyl transferase (GALT) gene. Hum Mutat. 1999;13(6):417-30. doi:10.1002/(SICI)1098-1004(1999)13:6<417::AID-HUMU1>3.0.CO;2-0.

Singh R, Thapa BR, Kaur G, Prasad R. Frequenct distribution of Q188R, N314D, Duarte 1, and Duarte 2 GALT variant alleles in an Indian galactosemia population. Biochem Genet. 2012 Dec;50(11-12):871-80. doi: 10.1007/s10528-012-9527-z.

University of Utah Database. Available from: http://www.arup.utah.edu/database/GALT/GALT_display.php.

Berry GT. Galactosemia: When is it a newborn screening emergency? Mol Genet Metab. 2012;106(1):7-11. doi:10.1016/j.ymgme.2012.03.007.

Beutler E, Baluda M, Donnell GN. A new method for the detection of galactosemia and its carrier state. J Lab Clin Med. 1964;64:694-705. PMID:14233158.

Varela-Lema L, Paz-Valinas L, Atienza-Merino G, Zubizarreta-Alberdi R, Villares RV, López-García M. Appropriateness of newborn screening for classic galactosaemia: a systematic reviewL. J Inherit Metab Dis. 2016;39(5):633-49. doi:10.1007/s10545-016-9936-y.

Welling L, Boelen A, Derks TG, et al. Nine years of newborn screening for classical galactosemia in the Netherlands: Effectiveness of screening methods, and identification of patients with previously unreported phenotypes. Mol Genet Metab. 2017;120(3):223-228. doi:10.1016/j.ymgme.2016.12.012.

Rybakova KD, Kuzmicheva NA. Biokhimicheskiye metody diagnostiki nasledstvennykh bolezney. [Biochemical methods of diagnosis of hereditary diseases]. Moscow: Meditsina; 1984. 32-35 pp. (in Russian).

Iboott FA. A screening procedure and a specific quantitative method for UDPglucose: alpha-D-galactose-1-phosphate uridylyltransferase (EC 2.7.7.12). Clin Chem. 1977;23(7):1348-55. PMID: 872388.

Mahmood U, Imran M, Naik SI, et al. Detection of common mutations in tne GALT gene through ARMS. Gene. 201210;509(2):291-4. doi:10.1016/j.gene.2012.08.010.

Jumbo-Lucioni PP, Garber K, Kiel J, et al. Diversity of approaches to classic galactosemia around the world: a comparison of diagnosis, intervention, and outcomes. J Inherit Metab Dis. 2012;35(6):1037-49. doi:10.1007/s10545-012-9477-y.

Ryan EL, Lynch ME, Taddeo E, Gleason TJ, Epstein MP, Fridovich-Keil JL. Cryptic residual GALT activity is a potential modifier of scholastic outcome in school age children with classic galactosemia. J Inherit Metab Dis. 2013;36(6):1049-61. DOI:10.1007/s10545-012-9575-x.

Rubio-Agusti I, Carecchio M, Bhatia KP, et al. Movement disorders in adult patients with classical galactosemia. Mov Disord. 2013;28(6):804-10. doi:10.1002/mds.25348.




DOI: https://doi.org/10.22141/2224-0551.13.1.2018.127066

Copyright (c) 2018 CHILD`S HEALTH

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта